Brief: Allergy Therapeutics Says G306 Phase III Trial Meets Key Endpoints

Allergy Therapeutics

13/12/2023 07:49

Dec 13 (Reuters) - Allergy Therapeutics PLC  AGY.L :
    * G306 PHASE III TRIAL MEETS KEY ENDPOINTS
    * POSITIVE PRIMARY AND SECONDARY ENDPOINTS OF G306 PIVOTAL
PHASE
III TRIAL INVESTIGATING GRASS MATA MPL ARE HIGHLY CONSISTENT
    * HIGHLY SIGNIFICANT SECONDARY EFFICACY ENDPOINTS WITH AN
ACCEPTABLE SAFETY AND TOLERABILITY PROFILE OBSERVED FOR GRASS
MATA MPL
    * NO UNEXPECTED SAFETY EVENTS WERE OBSERVED WITH GRASS MATA
MPL
27,600 SU
    * FIRST SCIENTIFIC ADVICE MEETING WITH REGULATORS IS
ANTICIPATED
TO OCCUR IN LATE Q1 2024

Source text for Eikon:  ID:nRSM5522Wa 
Further company coverage:  AGY.L 

 ((Reuters.Briefs@thomsonreuters.com;;))